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0022-2836/$ - see front matter © 2008 EBilirubin, an insoluble yellow-orange pigment derived from heme catabo-
lism, accumulates to toxic levels in individuals with impaired or immature
liver function. The resulting jaundice may be managed with phototherapy
to isomerize the biosynthetic 4Z,15Z-bilirubin-IXα to more soluble and
excretable isomers, such as 4Z,15E-bilirubin. Bilirubin and its configura-
tional isomers are transported to the liver by human serum albumin (HSA)
but their precise binding location(s) on the protein have yet to be
determined. To investigate the molecular details of their interaction, we
co-crystallised bilirubin with HSA. Strikingly, the crystal structure—
determined to 2.42 Å resolution—revealed the 4Z,15E-bilirubin-IXα isomer
bound to an L-shaped pocket in sub-domain IB. We also determined the co-
crystal structure of HSA complexed with fusidic acid, an antibiotic that
competitively displaces bilirubin from the protein, and showed that it binds
to the same pocket. These results provide the first crystal structure of a
natural bilirubin pigment bound to serum albumin, challenge some of the
present conceptions about HSA–bilirubin interactions, and provide a sound
structural framework for finally resolving the long-standing question of
where 4Z,15Z-bilirubin-IXα binds to the protein.© 2008 Elsevier Ltd. All rights reserved.Keywords: human serum albumin; bilirubin; crystal structure; fusidic acid;
ligand bindingEdited by R. HuberIntroduction
Bilirubin†, an orange-yellow pigment that results
from the breakdown of heme, is produced at a rate of
about 300 mg per day in human adults. The bio-
synthetic form of the bilirubin molecule (4Z,15Z-
bilirubin IXα; Fig. 1a), which is lipophilic and inso-
luble in water at neutral pH, is transported in blood
plasma by serum albumin to the liver where it is
converted to a water-soluble glucuronide that is
excreted into bile and ultimately eliminated via the
intestine.
The lipophilicity and poor aqueous solubility of
bilirubin was once something of a paradox, since theess:
rwise, all bilirubin
ubstituent
sed without
α diastereomer that is
tabolism.
serum albumin.
lsevier Ltd. All rights reservemolecule is a dicarboxylic acid containing several
polar functional groups. The paradox was resolved
when the crystal structure of the compound was
determined1 and revealed that the molecule adopts
a “ridge-tile” conformation in which the interplanar
angle between the dipyrrinone groups is about 100°,
allowing each of the two propionic acid groups to
make three hydrogen bonds with the opposite
dipyrrinone ring system and preventing them from
interacting with water (Fig. 1b). Later work showed
that the ridge-tile conformation occurs in solution,
although the bilirubin molecule can flip between two
enantiomeric conformers (P or M), both of which
maintain the internal hydrogen bond network2 (Fig.
1b). Further evidence of the flexibility of the molecule
came from the crystal structure of the di-isopropy-
lammonium salt of bilirubin.3,4 In the salt, the ridge-
tile conformation is largely retained, but some of the
intramolecular hydrogen bonds are replaced by
interactions with isopropylammonium counterions.
A similar exchange of intramolecular for intermole-
cular interactions is believed to occur on binding of
bilirubin to albumin,4 since thermodynamic evidence
shows that electrostatic interactions are important ford.
Fig. 1. Structure and stereochemistry of bilirubin and fusidic acid. (a) Structures of 4Z,15Z-bilirubin-IXα and the
photoisomer, 4Z,15E-bilirubin-IXα, that is observed bound to HSA in this study. Other possible configurational
photoisomers (4E,15Z-bilirubin and 4E,15E-bilirubin) are not shown. (b) Structures of theM and P enantiomers of 4Z,15Z-
bilirubin-IXα in the “ridge-tile” conformation. (c) Structure of fusidic acid.
395Human Serum Albumin–4Z,15E-Bilirubin-IXaprotein binding.5 Evidence from circular dichroism
studies shows that binding of bilirubin to human
serum albumin (HSA) is enantioselective, since the P
enantiomer is bound preferentially;6,7 however, pre-
cise details of the conformation adopted by bilirubin
when bound to the protein are lacking.
This issue is complicated by the photoisomerization
of bilirubin, a process that is relevant to the clinical
management of metabolic disorders involving thepigment. Bilirubin is normally present in plasma at
low concentration (5–17 μM) but, when conjugation
of bilirubin is deficient, the unconjugated pigment
accumulates in the circulation and extravascular
tissue, where it may become visually detectable
(jaundice). Jaundice is common in newborn infants
because of a transient developmental deficiency of
conjugation combined with increased hemoglobin
breakdown.8 In severe cases, the bilirubin-binding
396 Human Serum Albumin–4Z,15E-Bilirubin-IXacapacity of plasma albumin may be exceeded,
allowing sufficient bilirubin to cross the blood–brain
barrier and cause permanent neurological damage
(kernicterus). Phototherapywith blue orwhite light is
commonly used in the clinical management of
neonatal jaundice. The treatment enhances the
elimination of bilirubin by photochemically convert-
ing it to more polar photoisomers and low molecular
weight fragments that do not require conjugation
with glucuronic acid for excretion. Two types of
photoisomers are formed; structural and configura-
tional. In the latter, rotation around the Z configura-
tion C=C double bond within one or both of the
dipyrrinone moieties results in a configurational
change that partially or completely disrupts the
internal hydrogen bonding, thereby enhancing the
solubility and rate of secretion into the bile (Fig. 1a)
The reaction is reversible, and since the four config-
urational isomers have similar absorbance spectra,
irradiation of bilirubin with broad-spectrum light in
vitro eventually leads to a photostationary mixture of
all four in which the 4Z,15Z isomer invariably
predominates.9
Configurational photoisomerization of bilirubin
bound to HSA is highly regioselective for the C15
double bond and generates mainly the 4Z,15E iso-
mer.10 Although E photoisomers of bilirubin are
unstable in protic solvents, their thermal reversion to
the Z,Z isomer in the dark is very slowwhen they are
bound to HSA. The 4Z,15E-isomer is also the predo-
minant photoisomer present in the blood of neonates
undergoing phototherapy and in the blood of normal
adults after exposure to sunlight.8,11 Although
4Z,15E-bilirubin clearly interacts with HSA, little is
known about its locus or affinity of binding.
HSA, the primary transport vehicle for bilirubin
species in blood, is a highly soluble protein present
in plasma at a concentration of around 0.6 mM in
healthy adults. The monomeric protein is composed
of three structurally homologous helical domains (I,
II and III), each of which is divided into two sub-
domains (A and B).12 HSA preferentially binds
lipophilic anions and serves as a transporter for a
variety of small-molecule ligands. Its primary cargo
appears to be non-esterified fatty acids but the pro-
tein is also known to have a high affinity for other
endogenous anions, such as bilirubin, heme and
thyroxine.13 Moreover, HSA has a well-character-
ized affinity for lipophilic drug molecules that have
anionic or electronegative features.13
The 4Z,15Z-isomer of bilirubin binds with high
affinity (KD∼ 16 nM) to a single site onHSA.14 There
are also one or two secondary sites with affinities
that are at least tenfold lower.15 These are thought to
be unimportant in vivo but can complicate the inter-
pretation of in vitro binding experiments.16 Despite
numerous studies, the location of the primary
bilirubin-binding site on albumin is not known.
There is evidence that it is not in drug site 2, within
sub-domain IIIA,17 but evidence in favor of either
the heme-binding site in sub-domain IB18,19 or the
drug-binding site 1 in subdomain IIA20–22 is equi-
vocal and contradictory.To investigate the molecular details of the binding
of this important metabolite to albumin we com-
plexed bilirubin with HSA and determined the co-
crystal structure. We found that it binds to a primary
site in sub-domain IB of the protein but curiously,
the electron density indicates that the bound
pigment is predominantly the 4Z,15E isomer in a
distorted ridge-tile conformation, probably formed
via adventitious exposure of the 4Z,15Z complex to
light during the course of our experiments. We also
determined the co-crystal structure of HSA com-
plexed with the antibiotic fusidic acid, which has
been reported to compete with 4Z,15Z-bilirubin for
binding to albumin in vitro,23 and observed that it
occupies the same binding site in sub-domain IB as
4Z,15E-bilirubin. The results identify a new marker
for binding to domain IB and provide the first
evidence for the binding site of the clinically
important 4Z,15E photoisomer of bilirubin to HSA.
They also raise interesting questions about the loca-
tion on the protein of the primary binding site of the
biosynthetic 4Z,15Z isomer and suggest new ways
in which they might be resolved.Results
Structure determination of the HSA-bilirubin
complex
Bilirubin was incubated in the dark with HSA at
a 1.1:1 molar ratio of ligand to protein and co-
crystallised in a P1 unit cell that contains two mole-
cules in the asymmetric unit and is the same as that
obtained with other HSA–ligand complexes.24,25 A
complete X-ray diffraction dataset was collected
to 2.42 Å and phased by molecular replacement
(Materials andMethods). Following initial rigid body
refinement, calculation of a difference electron den-
sity map gave a clear indication of a single tetra-
pyrrole molecule bound to sub-domain IB of the
protein (Fig. 2a and b). There was also fragmentary
positive difference electron density in drug sites 1 and
2 (in sub-domains IIA and IIIA, respectively), but in
neither site was the density sufficient to guide the
building of even one dipyrrinone moiety of bilirubin.
In subsequent experiments, HSA-bilirubin was co-
crystallised from a 3:1molar ratio of bilirubin toHSA.
The structure of this complex was solved to 2.9 Å
resolution (data not shown); the electron density map
clearly confirmed the presence of pigment in sub-
domain IB but again contained only fragmentary
electron density in sub-domains IIA and IIIA that
could not be interpreted in molecular terms.
In contrast, the density in sub-domain IB gave a
good indication of the disposition of the dipyrri-
none chromophores and propionate side-chains of
the bound ligand (Fig. 2a). It was immediately
obvious that the ridge-tile conformation of 4Z,15Z-
bilirubin IXα that occurs in solution (Fig. 1b) could
not fit the density.2,26 Even if we allowed rotation
around the C9-C10 and C10-C11 bonds to disrupt
Fig. 2. Crystal structure of HSA complexed with 4Z,15E-bilirubin-IXα. (a) Simulated annealing Fo–Fc omit map
contoured at 1.75σ showing the pigment bound to sub-domain IB of HSA. 4Z,15E-bilirubin is shown in a stick
representation with atoms coloured by atom-type: C, yellow-orange; O, red; N, blue. Sub-domain IB is shown in a ribbon
representation (light red). (b) Overall structure of HSA complexed with 4Z,15E-bilirubin. The pigment is depicted with
space-filling spheres; the protein secondary structure is shown colored by sub-domain. (c) Detailed view of the
interactions of 4Z,15E-bilirubin with the binding pocket in sub-domain IB. Hydrogen bonds are indicated by broken
yellow lines. Selected protein sidechains are shown as sticks (with carbon atoms colored grey). (d) View of the fit of
4Z,15E-bilirubin (shown as a space-filling CPK model) to the pocket in sub-domain IB. (e) View of the fit of 4Z,15E-
bilirubin to the contours of the binding pocket in sub-domain IB (shown as a pink, semi-transparent surface). (f) Same as
in d but rotated ∼90° about a vertical axis.
397Human Serum Albumin–4Z,15E-Bilirubin-IXaintramolecular interactions and produce a more
extended conformation, it was not possible to
generate a reasonable fit; while this manipulation
allowed a match to three of the heterocyclic rings, it
could not account for the density corresponding to
the remaining ring. Instead, the electron density
suggested that one of the dipyrrinone groups hadadopted an E configuration; the best fit was
obtained by building the 4Z,15E isomer of bilirubin
in an orientation that placed the endo-vinyl dipyrri-
none moiety (with the Z configuration) in a predo-
minantly hydrophobic cleft generated by the pack-
ing of helices h8–h10 into a three-helix bundle (Fig.
2c), while the exo-vinyl dipyrrinone moiety (with
Table 1. Data collection and refinement statistics
HSA-4Z,15E-
bilirubin-IXα
HSA-fusidic
acid
A. Data collection
Space-group P1 P1
Unit cell parameters
a (Å) 55.09 55.17
b (Å) 55.54 55.32
c (Å) 119.83 119.83
α (°) 81.22 81.69
β (°) 90.70 90.73
γ (°) 65.42 65.83
Resolution range (Å) 38.07–2.42 35.33–3.05
Independent reflections 45,968 22,450
Multiplicity 1.8 (1.7) 1.9 (1.9)
Completeness (%) 95.0 (85.8) 92.4 (85.5)
I/σI 9.8 (2.2) 8.9 (1.9)
Rmerge (%)
a 4.5 (31.0) 7.7 (36.9)
B. Model refinement
Non-hydrogen atoms 8844 8967
Rmodel (%)
b 21.7 23.5
Rfree (%)
c 27.4 27.0
r.m.s.d. from ideal
Bond lengths (Å) 0.007 0.008
Bond angles (°) 1.17 1.18
Average B-factor (Å2) 78.4 58.2
Ramachandran plot 86.5/12.8 85.2/14.5
Most favoured regions (%)
Allowed regions (%)
PBD ID 2vue 2vuf
Values in parentheses are for the outermost resolution shell.
a Rmerge=100×∑h∑j|Ihj – Ih|/∑h∑jIhj, where Ih is the weighted
mean intensity of the symmetry-related reflections Ihj.
b Rmodel=100×∑hkl|Fobs – Fcalc|/∑hklFobs where Fobs and Fcalc are
the observed and calculated structure factors, respectively.
c Rfree isRmodel calculated using a randomly selected 5% sample
of reflection data omitted from the refinement.
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synclinal conformation) was accommodated in a
more open section of the pocket, packed against
helices h7-h8 and pinned underneath the polypep-
tide linker (residues 110–119) that connects IB with
the preceding sub-domain (Fig. 2c). This model
provides the best fit of the methyl and vinyl groups
on the planar endo-vinyl dipyrrinone group to the
observed density; it also allows both rings of the exo-
vinyl dipyrrinone moiety to be placed in density,
though the precise orientation of the outer lactam
ring is not clearly defined (Fig. 2a). It is noteworthy
that the M helicity of the bound 4Z,15E isomer is
consistent with CDmeasurements on the pigment in
the presence of HSA. (A. F. M., unpublished results).
Since the density for the bound pigment at the
current map resolution is not completely conti-
guous, we cannot rule out the possibility that the
4E,15Z isomer may be present also in some fraction
of the HSA molecules in the crystal. Nevertheless,
the interpretation that the 4Z,15E isomer is the pre-
dominant isomer bound within the crystal structure
is consistent with the observation that binding to
HSA favors photoisomerization of bilirubin to the
4Z,15E form.10
Although the 4Z,15E isomer provides the best fit
to the observed density and a plausible model for
4Z,15Z-bilirubin could not be made, the crystal-
lographic data do not exclude the possibility that
some fraction of the bound pigment is present in
this form. Modeling studies indicate that 4Z,15Z-
bilirubin may be able to fit within the binding site in
sub-domain IB in a partially extended conformation
in which the interplanar angle between the dipyrri-
none groups is increased from 100°, allowing the
molecule to adopt an overall shape that is broadly
similar to that built for the 4Z,15E isomer (though
some adjustments of the pocket side-chains would
be needed to avoid steric clashes). However, this
modeled conformation hasM-type helicity, which is
opposite to the P-type helicity observed in CD mea-
surements of 4Z,15Z-bilirubin bound to HSA. The
source of this inconsistency is not clear; although CD
measurements are very sensitive to conformational
changes in bilirubin, it is still difficult to derive a
precise model of protein-bound bilirubin conforma-
tions using CD data.7,27
The origin of the unexpected 4Z,15E photoisomer
is most likely intermittent exposure of the HSA–
bilirubin samples to ambient light during crystal-
lization, crystal manipulation and X-ray data collec-
tion. The original bilirubin used for the experiments
contained b2% 4Z,15E-bilirubin as determined by
HPLC analysis (data not shown). Control studies
showed that 4Z,15Z-bilirubin does not isomerize to
4Z,15E-bilirubin during several days incubation
with excess HSA in the dark at 37 °C. Although
precautions were taken to exclude light, samples
were exposed intermittently to light during solution
preparation and particularly during microscopic
examination. HPLC analyses of crystallization sam-
ples (crystals and mother liquor) confirmed the
presence of the 4Z,15E photoisomer at concentra-tions of up to ∼20% that of the 4Z,15Z isomer (data
not shown).
Structure of HSA complexed with
4Z,15E-bilirubin-IXα
The crystal structure of HSA complexed with
4Z,15E-bilirubin was fully refined to yield a model
with an Rfree of 27.4% with good stereochemistry
(Table 1). The pigment is bound within a central
channel formed by all four helices of sub-domain IB
and is evidently ”strapped” into place by the
extended polypeptide that connects this sub-domain
with sub-domain IA (residues 110–119) (Fig. 2) and
by the formation of salt-bridges with a pair of
arginine residues, R117 and R186, which lie at the
entrance to the binding cleft (Fig. 2c). Binding is
accompanied by only minor conformational
changes in some of the side-chains lining the binding
site, whereas the pigment is significantly distorted
from the ridge-tile conformation (though it broadly
maintains an L-shaped conformation).
The endo-vinyl dipyrrinone group, containing the
4Z double bond, maintains a syn-planar conforma-
tion and is accommodated in the deepest part of the
binding cleft, largely shielded from solvent. It makes
close contacts with the apolar side-chains of residues
399Human Serum Albumin–4Z,15E-Bilirubin-IXafrom helices h8–h10 (I142, F149, L154, F157, G189
and the aliphatic portion of K190) (Fig. 2c–e). The
carbonyl oxygen of the lactam ring is hydrogen-
bonded to the side-chain of Y138 (2.6 Å), though
neither of the two nitrogen atoms of the endo-vinyl
dipyrrinone group makes specific interactions with
the protein. Only one of the three intramolecular
hydrogen bonds made by this dipyrrinone group in
solution is retained in the bound conformation—
from the nitrogen on the pyrrole ring to the propio-
nate carboxylate group of the exo-vinyl dipyrrinone
group. This carboxylate group also makes a salt-
bridge interaction with the side-chain of R117 (2.7 Å).
The carboxylate group attached to the endo-vinyl
dipyrrinone group is in fact directed away from the
exo-vinyl dipyrrinone and makes no intramolecular
interaction when bound to HSA; instead, althoughFig. 3. Crystal structure of HSA complexed with fusidic ac
1.75σ showing the drug bound to sub-domain IB of HSA. Fu
colored by atom-type: C, light blue; O, red; N blue. (b) Overal
depicted with space-filling spheres, binds to sub-domains IB a
with the binding pocket in sub-domain IB. Hydrogen bond
sidechains are shown as sticks (with carbon atoms colored grey
sub-domain IB (pink, semi-transparent surface). (e) Same as inpartially shielded from solvent, it is oriented towards
the entrance to the pocket and makes a salt-bridge to
the side-chain of R186 (2.7 Å) (Fig. 2c).
A planar conformation for the exo-vinyl dipyrri-
none group that contains the 15E double bond is
unfavorable because of steric interactions of the
methyl substituents. As predicted by force-field
calculations,28 it occurs in a twisted syn-periplanar
conformation in a more exposed part of the cleft
formed by the polypeptide ”strap” and helices h7
and h8 (Fig. 2c and f). The inner pyrrole is bound
directly underneath the polypeptide strap, pinned
by apolar contacts with the side-chains of L115 and
R117, while the outer lactam ring is more exposed to
solvent. The E configuration allows the methyl and
vinyl substituents on the lactam ring to pack against
the hydrophobic flank of this part of the pocketid. (a) Simulated annealing Fo – Fc omit map contoured at
sidic acid is shown in a stick representation with atoms
l structure of HSA complexed with fusidic acid. The drug,
nd IIIB. (c) Detailed view of the interactions of fusidic acid
s are indicated by broken yellow lines. Selected protein
). (d) View of the fit of fusidic acid to the binding pocket in
d but rotated ∼90° about a vertical axis.
400 Human Serum Albumin–4Z,15E-Bilirubin-IXa(composed largely of the side-chains of P118, M123,
F134 and F165) but its amide and carbonyl groups
are exposed to solvent and appear to make no
contact with the protein. The NH of the inner
pyrrole is 3.1 Å from the carbonyl oxygen of L115
but the geometry for hydrogen bond formation is
poor. Thus the exo-vinyl dipyrrinone moiety of
4Z,15E-bilirubin makes no specific hydrogen bond
interactions with the protein.
Structure of the HSA–fusidic acid complex
Given the uncertainty in the literature regarding
the location of bilirubin binding on HSA, we sought
additional experimental support for the location of
the primary site. There is in vitro evidence that fusi-
dic acid competes with 4Z,15Z-bilirubin for bind-
ing to HSA,23 suggesting that both may bind to the
same pocket on the protein. The co-crystal struc-
ture of HSA-fusidic acid was determined to 3.05 Å
(Materials and Methods) and refined to yield a
model with an Rfree of 27.0% (Table 1). The crystal
structure reveals the presence of two fusidic acid
molecules associated with HSA (Fig. 3a and b). One
of these is bound to the outer surface of sub-domain
IIIB but also makes contact with a symmetry-related
HSAmolecule in the crystal, suggesting that this site
is therefore likely to be an artefact of co-crystal-
lisation. The other fusidic acid molecule is bound
entirely within sub-domain IB (Fig. 3b).
Strikingly, the fusidic acid adopts an L-shaped
conformation and occupies the binding pocket in
sub-domain IB in a manner very similar to that of
4Z,15E-bilirubin (Fig. 3c). The steroidmoiety is found
in the more open section of the binding pocket, lying
directly underneath the polypeptide strap and in
essentially the same position as the exo-vinyl dipyrri-
none group of 4Z,15E-bilirubin (Fig. 3d and e). The
side-chain hydroxyl of Y161 makes equidistant
hydrogen bonds (3.3 Å) with the two hydroxyl
groups that project from the steroid rings of fusidic
acid. Towards the other end of the drugmolecule, the
hydrocarbon tail of its methyl-heptenoic acid group
projects into the deeper part of the binding pocket
that was observed to be occupied by the endo-vinyl
dipyrrinone group of 4Z,15E-bilirubin (Fig. 3c and d),
but does not penetrate quite as far into this cavity;
thus derivatives of fusidic acid with larger apolar
substituents in this region might be expected to bind
with higher affinity. The acetyloxy and carboxylate
groups of fusidic acid are positioned at the entrance
to the pocket where they make hydrogen bond
interactions with R117 and R186 respectively (Fig.
3c), the same arginine residues that interact with the
carboxylate groups of 4Z,15E-bilirubin. Notably,
both of the Arg side-chains are significantly re-
oriented in order to establish these specific inter-
actions with the drug; an upward rotation of the
side-chain of R117 by about 40° is required to
provide room to accommodate the increased bulk of
the steroid moiety of fusidic acid. Elsewhere, there
are only minor differences in protein side-chain
conformations between the HSA complexes with4Z,15E-bilirubin and fusidic acid (primarily in-
volving L182, M123) and a small (0.8 Å) displace-
ment of the polypeptide strap.Discussion
Our crystallographic analysis of the complex
formed by incubating bilirubin with HSA unexpect-
edly yielded the structure of the clinically important
4Z,15E-bilirubin–HSA complex but nevertheless
provided intriguing new insights into the molecular
details of how this toxic bile pigment interacts with
its primary transporter.
With hindsight, it is clear that precautions to
exclude light were insufficiently rigorous and that
the 4Z,15E-isomer found in the crystals used for
structure determination was produced photochemi-
cally with each exposure of the crystallization mix-
ture to ambient light, particularly during repeated
microscopic examination of the sitting drops. Even
though the binding of bilirubin to HSA is known to
favor photoisomerization to the 4Z,15E form, the
crystallographic result is still something of a sur-
prise, because experiments in solution suggest that
this form does not usually exceed 40% of the bili-
rubin present due to rapid photo-equilibration bet-
ween the 4Z,15Z and 4Z,15E forms.10 One possible
explanation for our findings is that the 4Z,15E-
bilirubin isomer becomes locked in the binding site
in sub-domain IB due to close contacts between pro-
teins in the crystal. Earlier, we observed that ligands
that bind reversibly to HSA in solution can become
trapped in crystalline samples; for example, thyrox-
ine remained bound to its high-affinity site in sub-
domain IIA,29 even after back-soaking the HSA–
thyroxine crystals against thyroxine-free solutions
for periods in excess of 48 h (data not shown). How-
ever, further work is required to fully explain the
formation and isolation of crystalline HSA with the
4Z,15E form of bilirubin within site IB. Interestingly,
the crystal structure of the Z,E isomer of a symme-
trically substituted synthetic bilirubin has been re-
ported recently.30 This isomer also appears to have
been formed by incidental exposure of solutions to
light during attempts to crystallize the correspond-
ing Z,Z isomer.
If the 4Z,15E bilirubin observed in the crystal in
sub-domain IB was generated in situ from 4Z,15Z
bilirubin bound at the same site, the structure would
provide an explanation for the observation that
photo-isomerization of bilirubin bound to HSA is
highly regioselective for the exo-vinyl dipyrrinone.10
The crystal structure shows that the endo-vinyl
dipyrrinone moiety, which retains its planar Z
conformation during this photoisomerization, fits
snugly into the deep part of the binding cavity
formed by helices h8–h10. In particular, the contours
of the pocket appear well matched to the arrange-
ment of the methyl and vinyl groups that project
from adjacent carbon atoms of the outer lactam ring
(Fig. 2d). In contrast, the exo-vinyl dipyrrinone
moiety is held less tightly in a more open section of
401Human Serum Albumin–4Z,15E-Bilirubin-IXathe binding site (formed by the polypeptide strap
and helices h7-h8) that permits accommodation of
the twisted E conformation observed for the 4Z,15E
isomer. The structure suggests that the alternate
4E,15Z-isomer may bind less well, assuming that the
bound conformation is flipped to place the planar
exo-vinyl dipyrrinone group (Z conformation) in the
more enclosed portion of the binding cavity. This is
because the arrangement of the methyl and vinyl
groups on the outer lactam ring of the endo-vinyl
dipyrrinone group is the reverse of that on the exo-
vinyl dipyrrinone group and does not therefore
allow a precise fit inside the cavity; indeed, we
would predict a steric clash between the vinyl group
and the side-chain of F157. The structure thus
suggests that photoisomerization to the 4Z,15E
form would be favored by binding of 4Z,15Z-
bilirubin to sub-domain 1B because the open section
of the pocket has sufficient room and flexibility to
permit rotation of the exo-vinyl lactam ring on
photoexcitation.
Is sub-domain IB the primary binding site for
4Z,15Z-bilirubin IXα on HSA?
This is a key question, since the 4Z,15Z-isomer of
bilirubin is the predominant form in vivo.31 From
our data, it is impossible to deduce whether the
4Z,15E-bilirubin observed in the crystal was formed
from 4Z,15Z-bilirubin initially bound to the same
site or whether it was formed by photoisomerization
of 4Z,15Z-bilirubin bound to another site followed
by migration of the 4Z,15E isomer to subdomain IB.
Although the new crystallographic data presented
here supply no direct evidence for the hypothesis
that 4Z,15Z-bilirubin IXα binds primarily to sub-
domain IB of HSA, they offer some indirect support
that is worth considering. The crystal structure
clearly shows that sub-domain IB contains a pre-
formed L-shaped binding cavity that is the appro-
priate size to accommodate the 4Z,15E isomer of
bilirubin (Figs. 1a, and 2e and f). Modeling studies
suggest that binding of the 4Z,15Z-isomer could be
achieved in the same pocket with only relatively
minor adjustments of the pigment (to open up the
ridge-tile conformation that is observed in solu-
tion2), and of some of the side-chains and the
polypeptide strap in sub-domain IB. Comparison of
the HSA-bilirubin and HSA-fusidic acid complexes
shows that the flexibility of side-chains lining the
pocket confers considerable adaptability, allowing it
to form specific interactions with different ligands
(Fig 4a and c; see below). Moreover, the observa-
tion that fusidic acid binds specifically to sub-
domain IB provides a plausible explanation for
the observation that this drug competes with
bilirubin—presumed to be in its 4Z,15Z form—for
binding to the protein.23
Nevertheless, the location of the primary binding
site for bilirubin on HSA remains to be established.
Although the most recent reviews that have con-
sidered the question have tended to highlight sub-
domain IIA (drug site 1) as the primary binding sitefor bilirubin,13,32 the evidence accumulated over
many years is actually rather equivocal on this point.
One of the earliest attempts to locate binding sites
for bilirubin on albumin compared the binding
affinity of a range of proteolytic fragments of BSA.22
Such experiments can be difficult to interpret even
when the structure of the intact protein is known,
because the structural impact of proteolysis is not
predictable. The authors of the study identified
residues 186–238, which comprise most of sub-
domain IIA, as a region common to fragments that
retained high-affinity binding. However, this inter-
pretation may under-estimate the significance of the
large variations in affinity between fragments con-
taining this region. For example, although fragment
186–306 (sub-domain IIA) had a KA of 5.4×106 M
−1,
this is about tenfold lower than the bilirubin-binding
affinity of the fragment 1–306 (sub-domains IA-IB-
IIA). This could suggest that locations outside sub-
domain IIA may contribute significantly to high-
affinity binding.
Other approaches probed the ability of albumin-
binding drugs to displace bilirubin from the protein
as a means to localize its binding site. This method
has the advantage of using intact protein, although
the presence of primary and secondary binding sites
for the competing ligands can complicate the
interpretation of the results. One study of this type
showed that diazepam, a drug site 2 compound that
binds specifically and uniquely to sub-domain
IIIA,24 did not displace bilirubin from its primary
site.17 This result, which was the first demonstration
of co-binding of two ligands to a single polypeptide,
suggests that bilirubin does not bind primarily to
sub-domain IIIA. Against this, it has been found that
ibuprofen—another drug that binds primarily to
drug site 2—can displace bilirubin from HSA.33 A
precise interpretation of this latter result is difficult,
since recent data show that ibuprofen also binds to
two secondary sites in sub-domain II, one of which
is co-incident with drug site 1.24
Investigations using compounds that bind speci-
fically to drug site 1 in sub-domain IIA have
produced results that are non-trivial to interpret at
the molecular level. Thus warfarin, phenylbutazone,
azapropazone, indomethacin, iophenoxic acid and
thyroxine were all found to displace bilirubin from
the protein,20,23,34–37 findings that at first sight are
consistent with sub-domain IIA being the primary
locus of bilirubin binding. However, in some cases
displacement of bilirubin was observed only at high
concentrations of competitor,20,34–36 which raises the
possibility that displacement of bilirubin may be
due to drug binding at secondary sites outside sub-
domain IIA. In fact, Fehske and colleagues con-
cluded that the site 1 drugs warfarin, azapropazone
and phenylbutazone did not compete with the
primary bilirubin site. For several of the competitor
compounds used in these studies (warfarin, azapro-
pazone, indomethacin and iophenoxic acid), crystal-
lographic analysis has revealed secondary binding
sites in sub-domain IB24,38 (A. Ryan and S. C.,
unpublished results) which is consistent with the
Fig. 4. The flexible binding capacity of sub-domain IB in HSA. (a, c) Comparative binding of 4Z,15E-bilirubin and
fusidic acid. Ligands are shown in a stick representation with yellow-orange (4Z,15E-bilirubin) or light-blue (fusidic acid)
carbon atoms. (b, d) Comparative binding of oleic acid55 and hemin.45 Ligands are shown in a stick representation with
dark grey (oleic acid) or light-green (hemin) carbon atoms. (c and d) Top view relative to the orientation shown in (a) and
(b). Variation in the geometry of the binding pocket in sub-domain IB is evident from the surface representation of the
protein shown for the complex with 4Z,15E-bilirubin (e) and the complex with hemin (f). Binding of hemin, but not
4Z,15E-bilirubin, induces large rotations of Y138 and Y161 which open up a D-shaped cavity that extends to the back of
the sub-domain.
402 Human Serum Albumin–4Z,15E-Bilirubin-IXanotion that some of the displacement activity may
be attributed to the binding of bilirubin to this site.
More recent investigations used site-directed
mutagenesis to test the hypothesis that sub-domain
IIA is the primary binding site for bilirubin. Eight
different amino acid substitutions were introduced
into sub-domain IIA but in no case was a significantreduction in the binding affinity observed,21 sug-
gesting that the pigment binds elsewhere on the
protein. This result is in contrast to a parallel inves-
tigation that found some of the same mutations
caused a significant decrease in the binding affinity
of warfarin,39 a drug that is known to bind within
sub-domain IIA. Nevertheless, several of the
403Human Serum Albumin–4Z,15E-Bilirubin-IXamutations in IIA had a very marked impact on the
CD spectra obtained from HSA–bilirubin
complexes,21 consistent with the notion that bilir-
ubin binds primarily within that sub-domain. As
yet, it has not been possible to reconcile these
apparently divergent observations, though it is
intriguing to note reports of possible allosteric
interactions between the heme binding site in sub-
domain IB and drug site 1 in sub-domain IIA.40
Experiments that have addressed the question of
competition between bilirubin and hemin directly
have generally found that thesemolecules can bind to
albumin independently,18,41,42, although some com-
petition was observed at high ligand to HSA molar
ratios.19 Since the hemin-binding site on albumin
has been located unequivocally in sub-domain
IB,43–45 these data therefore suggest that the primary
bilirubin-binding site on the protein lies outside sub-
domain IB. Curiously, one of these studies found that
hemin competed with MADDS (monoacetyldiami-
nodiphenyl sulphone),18 a compound that has been
shown to be an effective marker for the high-affinity
site for bilirubin (and is displaced by fusidic acid).23
The interaction between hemin and bilirubin on HSA
clearly warrants further investigation.
Overall, it has not been possible to arrive at a
definitive assignment of the location of the high-
affinity binding site for 4Z,15Z-bilirubin on HSA.
Our results at least raise the interesting possibility
that the binding site is located within sub-domain
IB. This would readily explain the displacement of
bilirubin by fusidic acid, which we have also shown
to bind to sub-domain IB. It is consistent also with
some of the existing literature on bilirubin binding,
but—as discussed above—there are many observa-
tions that conflict with this hypothesis. Although we
observed only weak difference density in sub-
domain IIA that was insufficient to allow modeling
of bilirubin at this site, other crystallographic data
show how molecules that are similar in dimensions
to bilirubin, such as iodipamide, might be accom-
modated in this sub-domain.24
The structural information presented in this re-
port will allow the design of new experimental
approaches to determine the site of bilirubin bind-
ing. For example, it would be interesting to examine
the effect of mutating residues in sub-domain IB that
are observed to contact 4Z,15E-bilirubin-IXα (e.g.
L115, R117, Y138, F157, and G189) to determine if
they have an effect on the binding of the 4Z,15Z
isomer. Moreover, the accumulating database of
crystal structures of HSA–drug complexes24,38,46 has
engendered a much more detailed understanding of
the binding locations of a wide range of small
molecule compounds that might now be used for
more finely controlled competition binding experi-
ments. Further efforts to obtain crystals of HSA
complexed with 4Z,15Z bilirubin should also be
informative, although our experience indicates that
preparation and crystallization of the complex is
likely to require stringent working under orange or
red safelights to prevent the formation of the 4Z,15E
isomer. This approach was used successfully in thedetermination of the structure of rhodopsin while
maintaining its chromophore, retinol, in the ground
state.47
Sub-domain IB on HSA provides a flexible and
versatile binding pocket
The structural data on HSA complexes with
4Z,15E-bilirubin and fusidic acid provide fresh
insight into the versatile binding capacity of this re-
markable transport protein. Both ligands bind into an
essentially pre-formed L-shaped cavity within sub-
domain IB, their interactions with the protein largely
involving side-chain adjustments. The mode of
binding of these two ligands to HSA contrasts
markedly with the binding of other compounds
such as fatty acids or hemin, both of which induce a
significant conformational rearrangement of sub-
domain IB (Fig. 4). In particular, binding of fatty
acids or hemin causes the side-chains of Y138 and
Y161 to un-stack, each tyrosine rotating ∼90° to
opposite sides of the binding cavity and thereby
redefining the pocket geometry (Fig. 4a and b).45,48,49
Y138 moves to form the outside flank of the pocket,
largely closing off the entrance to the more open
section of the cavity that is bound by the exo-vinyl
dipyrrinone moiety of the rubin (or the steroid rings
of fusidic acid); Y161 lies against the other wall of the
cavity. In their new positions the aromatic rings of the
two tyrosines are placed flat in contact with the
bound ligand, like a pair of hands holding it in place
(Fig. 4c–f). The newly formed cavity is D-shaped, and
can fully accommodate the planar porphyrin ring of
hemin. The methylene tails of fatty acids bound to
this pocket curve around the back wall; this leaves
sufficient room for co-binding of aromatic drugs or
drug-like molecules such as indomethacin and tri-
iodobenzoic acid.24,50
A further intriguing aspect of the flexibility of the
binding pocket in sub-domain IB is the rearrange-
ment of the basic residues at the main entrance to
interact with the polar features presence on the
different ligands. Thus R117 is engaged in interac-
tions with bound fatty acid, 4Z,15E-bilirubin and
fusidic acid (Fig. 4a-d) but in each case varies its
side-chain orientation in order to accommodate the
variable positions of the polar carboxyl or acetyloxy
groups of the different ligands. R186 is observed to
interact only with rubin and fusidic acid (Fig. 4a,
and c), again adjusting its position to maintain
interactions with the ligand. Hemin, by contrast,
interacts with neither of these Arg residues; instead
its two propionic acid groups are coordinated by
R114, H146 and K190 (Fig. 4b and f).Materials and Methods
Preparation and crystallization of the HSA complexes
Recombinant HSA (Recombumin®) obtained from
Delta Biotechnology (Nottingham, UK), was defatted
404 Human Serum Albumin–4Z,15E-Bilirubin-IXaand purified by gel-filtration chromatography to be
dimer-free essentially as described,25,50 and then concen-
trated to 100 mg/ml (1.5 mM). Bilirubin (Sigma-Aldrich)
containing 6% 4Z,15Z-bilirubin IIIα, 87% 4Z,15Z-bilirubin
IXα and 5% 4Z,15Z-bilirubin XIIIα and b2% Z,E isomers
(as determined by HPLC)51 was dissolved immediately
before use at 10 mM in dimethylsulfoxide (DMSO) in a
foil-wrappedmicrocentrifuge tube. The bilirubin andHSA
solutions were mixed to give a bilirubin to HSA molar
ratio of 1.1:1 and 3:1, and incubated with rotation in the
dark overnight at room temperature. Finally, the complex
was washed with repeated cycles of concentration and
dilution with 50 mM potassium phosphate buffer (pH 7.0)
using a 5 kDa cut-off ultrafiltration device (Vivaspin,
Millipore) to reduce the final concentration of DMSO to
b0.1% (v/v).
The exposure of HSA–bilirubin solutions and crystals to
light was minimized throughout our procedures but not
eliminated. Manipulation of solutions (e.g. mixing of HSA
and bilirubin or setting up crystallization trials) was
performed under ambient natural light but all long-term
incubations were performed in foil-wrapped containers
stored in a light-proof refrigerator. Periodically, crystal-
lization trials were inspected briefly under a microscope
with dim illumination. Crystals were mounted in capil-
laries under the same conditions and then transported to
the synchrotron in foil-wrapped containers. Immediately
before data collection, the crystal was mounted on the
X-ray camera under ambient light which was then turned
off for the 45–90 min required to collect an X-ray dif-
fraction dataset.
Fusidic acid was dissolved at 10 mM in water and mixed
with 1.5 mMHSA to obtain a 3:1 molar ratio of fusidic acid
to HSA. The resulting complex was concentrated to around
100 mg/ml in a single step by ultrafiltration.
In each case, complexes were analyzed by PAGE to
estimate the concentration of protein. Crystals were
grown by the sitting-drop, vapor-diffusion method at 4
°C using methods similar to those described else-
where.49,50,52 Crystallization screens were set up at a
protein concentration of N90 mg/ml using 20–30% (w/v)
PEG 3350 (Sigma-Aldrich) in 50 mM potassium phosphate
buffer (pH 7.0) as the precipitant, with sitting drops
prepared by mixing 4 μl of the protein solution and 4 μl of
the reservoir mixture. Crystals were observed one to three
days after streak-seeding, the largest appearing at 24%
(w/v) PEG for fusidic acid and 26% (w/v) PEG for
bilirubin.
Data collection, processing, structure determination
and refinement
X-ray diffraction data were collected at Daresbury SRS
(station 9.6) and EMBL/DESY Hamburg (beamline X11)
using crystals mounted in sealed glass capillaries at room
temperature at least 24 h before data collection. Mounted
crystals were stored at 4 °C and transported in insulated
containers chilled with ice-packs. The diffraction data
were collected at room temperature, and it was possible to
get a full dataset from a single crystal for both complexes.
The data were indexed and measured with MOSFLM
(Medical Research Council, Laboratory of Molecular
Biology, Cambridge, UK) and scaled using the CCP4
suite.53 A previously determined structure of HSA (PDB
ID code 2bxa24) stripped of its ligand was used as a
starting model for phasing. Rigid body, positional and B-
factor refinements were performed using CNS.54 Data
collection and refinement statistics are summarized in
Table 1.Protein Data Bank accession numbers
Coordinates and structure factors have been deposited
in the Protein Data Bank with accession numbers 2vue
(HSA-4Z,15E-Bilirubin-IXα) and 2vuf (HSA-fusidic acid).Acknowledgements
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